Insightful Word
  • Investing
  • Stock
  • Economy
  • Politics
  • Investing
  • Stock
  • Economy
  • Politics
No Result
View All Result
Insightful Word
No Result
View All Result
Home Stock

SELLAS shares tumble on interim trial results

admin by admin
January 23, 2025
in Stock
0
SELLAS shares tumble on interim trial results
0
SHARES
4
VIEWS
Share on FacebookShare on Twitter

Investing.com — SELLAS Life Sciences stock fell 14% following the outcome of the interim analysis for its pivotal Phase 3 REGAL trial of GPS in Acute Myeloid Leukemia (AML). The Independent (LON:IOG) Data Monitoring Committee (IDMC) recommended the trial to continue without modifications, despite the market’s negative response.

The interim analysis, conducted after 60 events (deaths) in the study population, was intended to assess the safety, potential efficacy, and continuation merit of the therapy. The IDMC found that the data supported the continuation of the study according to its original protocol. While the company’s CEO, Angelos Stergiou, expressed optimism about the IDMC’s recommendation and the potential of GPS to become a transformative treatment for AML, investors reacted negatively to the news.

SELLAS remains blinded to the trial outcomes to maintain study integrity, but select blinded data has shown a pooled median survival exceeding 12 months, which is favorable compared to the expected 6 months in a similar patient population. Additionally, an early immune response analysis in a sample of patients receiving GPS indicated an 80% GPS-specific immune response.

These outcomes align with previous GPS trials, where the median overall survival for GPS-treated patients was 21 months versus 5.4 months for patients on standard of care therapy. Despite these promising interim results and the company’s ongoing preparations for a Biologics License Application (BLA), the market’s reaction suggests concerns about the final trial outcomes and regulatory approval process.

Dr. Yair Levy, Director of Hematologic Malignancies Research at Texas Oncology Baylor University Medical (TASE:PMCN) Center, conveyed hope for the therapy’s potential, based on previous trial outcomes, and indicated that GPS could become a new standard of care for AML patients in remission. He emphasized the therapy’s tolerability and minimal side effects, which are significant considering the severe side effects experienced by up to 60% of patients under standard therapies.

The REGAL trial is an open-label registrational clinical trial for GPS in AML patients in their second complete remission, with overall survival as the primary endpoint. The IDMC, consisting of independent medical, scientific, and biostatistics experts, is responsible for reviewing patient safety and efficacy data and ensuring the study’s validity and merits. The final analysis will be conducted after reaching 80 events, which is anticipated to occur this year.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

This post appeared first on investing.com

Previous Post

US weekly jobless claims increase marginally

Next Post

Volkswagen to make added investments in United States, CFO says at Davos

admin

admin

Next Post
Volkswagen to make added investments in United States, CFO says at Davos

Volkswagen to make added investments in United States, CFO says at Davos

Trending News

COMAC dreams of international skies: can the Chinese aircraft manufacturer rival Boeing and Airbus?

COMAC dreams of international skies: can the Chinese aircraft manufacturer rival Boeing and Airbus?

January 20, 2025
Could PepeX benefit as Europe ramps up AI investments?

Could PepeX benefit as Europe ramps up AI investments?

April 2, 2025
Dow and S&P 500 extend gains after Fed rate cut; Tesla hits $1T, chip stocks slip

Dow and S&P 500 extend gains after Fed rate cut; Tesla hits $1T, chip stocks slip

November 9, 2024
Subscribe to Insightful Word


    Recent News

    China’s May export growth seen slowing to 5.0% amid trade uncertainty: Reuters poll

    China’s May export growth seen slowing to 5.0% amid trade uncertainty: Reuters poll

    June 6, 2025
    FTSE 100 Index shares of 2025: Rolls-Royce, Fresnillo, BAE, and more

    FTSE 100 Index shares of 2025: Rolls-Royce, Fresnillo, BAE, and more

    June 6, 2025
    Asian stocks end mixed: Hang Seng snaps winning streak, Nikkei jumps 0.5%

    Asian stocks end mixed: Hang Seng snaps winning streak, Nikkei jumps 0.5%

    June 6, 2025
    Starlink reportedly secures key licence in India, moves closer to launching services

    Starlink reportedly secures key licence in India, moves closer to launching services

    June 6, 2025

    Recent News

    China’s May export growth seen slowing to 5.0% amid trade uncertainty: Reuters poll

    China’s May export growth seen slowing to 5.0% amid trade uncertainty: Reuters poll

    June 6, 2025
    FTSE 100 Index shares of 2025: Rolls-Royce, Fresnillo, BAE, and more

    FTSE 100 Index shares of 2025: Rolls-Royce, Fresnillo, BAE, and more

    June 6, 2025

    Latest News

    • China’s May export growth seen slowing to 5.0% amid trade uncertainty: Reuters poll
    • FTSE 100 Index shares of 2025: Rolls-Royce, Fresnillo, BAE, and more
    • Asian stocks end mixed: Hang Seng snaps winning streak, Nikkei jumps 0.5%

    About Insightful Word

    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools
    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools

    Copyright © 2025 Insightfulword.com. All Rights Reserved.

    No Result
    View All Result
    • Investing
    • Stock
    • Economy
    • Politics

    Copyright © 2025 Insightfulword.com. All Rights Reserved.